Aier(SZ:300015) Xin Lang Cai Jing·2025-05-02 06:47Core Insights - The company reported a total revenue of 20.983 billion yuan for 2024, representing a year-on-year growth of 3.02%, and a net profit attributable to shareholders of 3.556 billion yuan, up 5.87% [1] - For Q1 2025, the company achieved a total revenue of 6.026 billion yuan, reflecting a year-on-year increase of 15.97%, and a net profit of 1.050 billion yuan, which is a 16.71% growth [1] - The company experienced steady overseas growth with overseas revenue reaching 2.625 billion yuan, a 13.53% increase, while domestic revenue was 18.358 billion yuan, a modest rise of 1.68% [1] Financial Performance - The company's gross profit margin decreased by 2.67 percentage points to 48.12% in 2024 [1] - The company plans to distribute a cash dividend of 1.6 yuan per 10 shares, totaling 1.487 billion yuan, which accounts for 41.82% of the net profit attributable to shareholders for 2024 [2] - The company executed two share repurchase plans, buying back 31,363,178 shares, which is 0.34% of the total share capital, for a total amount of 586 million yuan [2] Growth and Strategy - The company reported an outpatient volume of 16.9407 million visits, a year-on-year increase of 12.14%, and a surgical volume of 1.2947 million cases, up 9.38% [1] - The company is advancing its "AI + ophthalmology" application strategy, launching the AierGPT model in September 2024, aimed at enhancing eye health education, diagnosis, training, and management [1] Future Outlook - Revenue projections for 2025-2027 are 25.147 billion, 29.128 billion, and 33.243 billion yuan, with expected growth rates of 19.8%, 15.8%, and 14.1% respectively [2] - Net profit forecasts for the same period are 4.387 billion, 5.159 billion, and 5.982 billion yuan, with growth rates of 23.4%, 17.6%, and 16.0% respectively [2]